Azure Synthetics Azure Synthetics Research peptides, clearly documented.
SS-31 / Elamipretide

Mitochondrial + redox research

SS-31 / Elamipretide

Lyophilized mitochondrial and cellular-signaling research material

SS-31 / Elamipretide is a mitochondria-targeting peptide studied around cardiolipin interaction, mitochondrial membrane function, and oxidative-stress models.

価格帯: 48.99 $ – 662.99 $
99.0%-99.5% Lyophilized powder 10 mg
Available documentation

Support can confirm any currently available COAs or batch documentation for this product.

Request available documents

For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.

Storage

Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.

Shipping notes

Packed for transit stability with order support available for warm-weather routes.

Batch reference

Batch-linked certificate support is available through the documentation desk.

研究背景

SS-31 / Elamipretide 研究プロファイル

SS-31, also called elamipretide in pharmaceutical research, is a mitochondria-targeting tetrapeptide studied for interaction with cardiolipin in the inner mitochondrial membrane. Experimental work measures membrane structure, electron-transport function, reactive-oxygen-species markers, ATP-related endpoints, and tissue responses to mitochondrial stress. It differs from MOTS-c, which is approached as a mitochondrial-derived signaling peptide, and from NAD+, which is a redox coenzyme. SS-31 is most useful when membrane and cardiolipin biology are central to the study design. A substantial preclinical and clinical-development literature exists, but reported outcomes vary by model and do not validate a separate catalog material.

Molecular class

Four-residue mitochondria-targeting peptide

Sequence / composition

D-Arg-2,6-dimethylTyr-Lys-Phe-NH2; an aromatic-cationic tetrapeptide also known as elamipretide.

Research design note

Its charge and aromatic residues drive inner-membrane and cardiolipin-focused experimental models.

想定される機序

A mitochondria-targeting tetrapeptide proposed to associate with cardiolipin in the inner mitochondrial membrane. This interaction may stabilize membrane curvature and respiratory-chain organization, reduce electron leak, and limit excess reactive-oxygen-species generation.

研究で報告された作用

  • Cell and animal models report improved mitochondrial respiration, ATP-related measures, membrane potential, and resistance to oxidative injury.
  • Preclinical studies report functional improvements in selected cardiac, skeletal-muscle, renal, neurologic, and ocular disease models.
  • Human clinical-development studies have produced mixed results across indications and endpoints.

一般的な研究エンドポイント

Cardiolipin interaction, oxygen consumption, electron transport, ATP, membrane potential, reactive oxygen species, mitochondrial morphology, tissue function, pharmacokinetics, and clinical endpoints.

エビデンスと限界

The mechanistic and preclinical literature is extensive, but human efficacy has not been consistent across clinical programs.

External reading

Literature for context—not product proof.

Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.

Support and documentation

Questions about this product?

Where can I find product documentation?

Contact support with the product name and any relevant order or batch reference to request available documents.

How can I compare pack options?

Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.